文献速递产科母胎医学

阴道孕酮预防双胎妊娠早产及不良围产结局:系统综述与Meta分析

Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in twin gestations: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2023-05-15

本系统综述与Meta分析纳入11项随机对照试验(3401名孕妇、6802名胎儿/婴儿),评估阴道孕酮对双胎妊娠早产及不良围产结局的预防效果。在全部双胎妊娠中,阴道孕酮与安慰剂或不治疗相比在早产风险上无显著差异;在经阴道超声宫颈长度<30 mm或≤25 mm的双胎妊娠中,阴道孕酮与部分早产及新生儿结局风险降低相关,但证据质量多为中等。

要点

  • 全部双胎妊娠中,阴道孕酮对<34周、<37周、<28周早产及自发早产均无显著影响。
  • 经阴道超声宫颈长度<30 mm的双胎妊娠中,阴道孕酮与<28至<32周早产、新生儿死亡及出生体重<1500 g风险降低相关(中等至高质量证据)。
  • 宫颈长度≤25 mm的双胎妊娠中,阴道孕酮与<28至<34周早产、复合新生儿疾病和死亡及出生体重<1500 g风险降低相关(中等质量证据)。

核心结论

  • 阴道孕酮不能预防未选择双胎妊娠的早产,也不改善其围产结局,但似乎可降低超声提示宫颈缩短的双胎妊娠早期早产及新生儿疾病和死亡风险。
  • 作者指出,在向这一部分患者推荐该干预措施之前,还需要更多证据。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、LILACS、CINAHL(自建库至2023年1月31日)、Cochrane数据库、Google Scholar、参考文献目录及会议论文集。
  • 纳入比较阴道孕酮与安慰剂或不治疗的纳入无症状双胎妊娠妇女的随机对照试验,共11项研究(3401名妇女、6802名胎儿/婴儿)。
  • 按照Cochrane干预措施系统综述手册进行,计算合并相对危险度(RR)及95%置信区间(CI),并评估偏倚风险、异质性、发表偏倚及证据质量。

主要发现

  • 全部双胎妊娠中,阴道孕酮组与安慰剂或不治疗组比较:<34周早产RR 0.99(95%CI 0.84-1.17,高质量证据),<37周早产RR 0.99(95%CI 0.92-1.06,高质量证据),<28周早产RR 1.00(95%CI 0.64-1.55,中等质量证据),<34周自发早产RR 0.97(95%CI 0.80-1.18,高质量证据)。
  • 亚组分析未发现绒毛膜性、受孕类型、自发性早产史、阴道孕酮每日剂量及开始治疗时孕周对<34周早产效果存在差异的证据。
  • 未选择双胎妊娠(8项研究;3274名妇女、6548名胎儿/婴儿)中,<37、<34、<32、<30、<28周早产频率及不良围产结局在两组间均无显著差异。
  • 宫颈长度<30 mm的双胎妊娠(6项研究;306名妇女、612名胎儿/婴儿)中,阴道孕酮与<28至<32周早产风险降低相关(RR 0.48-0.65,中等至高质量证据),与新生儿死亡风险降低相关(RR 0.32,95%CI 0.11-0.92,中等质量证据),与出生体重<1500 g风险降低相关(RR 0.60,95%CI 0.39-0.88,高质量证据)。
  • 宫颈长度≤25 mm的双胎妊娠(6项研究;95名妇女、190名胎儿/婴儿)中,阴道孕酮与<28至<34周早产风险降低相关(RR 0.41-0.68),与复合新生儿疾病和死亡风险降低相关(RR 0.59,95%CI 0.33-0.98),与出生体重<1500 g风险降低相关(RR 0.55,95%CI 0.33-0.94),这些结局的证据质量均为中等。

关键数值与推荐

  • 全部双胎妊娠中,阴道孕酮与安慰剂或不治疗相比,<34周早产风险无显著差异(RR 0.99,95%CI 0.84-1.17,高质量证据)。
  • 宫颈长度<30 mm的双胎妊娠中,阴道孕酮与新生儿死亡风险降低相关(RR 0.32,95%CI 0.11-0.92,中等质量证据)。
  • 宫颈长度≤25 mm的双胎妊娠中,阴道孕酮与复合新生儿疾病和死亡风险降低相关(RR 0.59,95%CI 0.33-0.98,中等质量证据)。

临床怎么用

  • 作者认为,阴道孕酮似乎可降低超声提示宫颈缩短的双胎妊娠早期早产及新生儿疾病和死亡风险,但在向这一部分患者推荐该干预措施之前,还需要更多证据。

局限性

  • 作者指出,在向超声提示宫颈缩短的双胎妊娠患者推荐阴道孕酮之前,还需要更多证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations. DATA SOURCES: MEDLINE, Embase, LILACS, and CINAHL (from their inception to January 31, 2023), Cochrane databases, Google Scholar, bibliographies, and conference proceedings. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials that compared vaginal progesterone to placebo or no treatment in asymptomatic women with a twin gestation. METHODS: The systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions. The primary outcome was preterm birth <34 weeks of gestation. Secondary outcomes included adverse perinatal outcomes. Pooled relative risks with 95% confidence intervals were calculated. We assessed the risk of bias in each included study, heterogeneity, publication bias, and quality of evidence, and performed subgroup and sensitivity analyses. RESULTS: Eleven studies (3401 women and 6802 fetuses/infants) fulfilled the inclusion criteria. Among all twin gestations, there were no significant differences between the vaginal progesterone and placebo or no treatment groups in the risk of preterm birth <34 weeks (relative risk, 0.99; 95% confidence interval, 0.84-1.17; high-quality evidence), <37 weeks (relative risk, 0.99; 95% confidence interval, 0.92-1.06; high-quality evidence), and <28 weeks (relative risk, 1.00; 95% confidence interval, 0.64-1.55; moderate-quality evidence), and spontaneous preterm birth <34 weeks of gestation (relative risk, 0.97; 95% confidence interval, 0.80-1.18; high-quality evidence). Vaginal progesterone had no significant effect on any of the perinatal outcomes evaluated. Subgroup analyses showed that there was no evidence of a different effect of vaginal progesterone on preterm birth <34 weeks of gestation related to chorionicity, type of conception, history of spontaneous preterm birth, daily dose of vaginal progesterone, and gestational age at initiation of treatment. The frequencies of preterm birth <37, <34, <32, <30, and <28 weeks of gestation and adverse perinatal outcomes did not significantly differ between the vaginal progesterone and placebo or no treatment groups in unselected twin gestations (8 studies; 3274 women and 6548 fetuses/infants). Among twin gestations with a transvaginal sonographic cervical length <30 mm (6 studies; 306 women and 612 fetuses/infants), vaginal progesterone was associated with a significant decrease in the risk of preterm birth occurring at <28 to <32 gestational weeks (relative risks, 0.48-0.65; moderate- to high-quality evidence), neonatal death (relative risk, 0.32; 95% confidence interval, 0.11-0.92; moderate-quality evidence), and birthweight <1500 g (relative risk, 0.60; 95% confidence interval, 0.39-0.88; high-quality evidence). Vaginal progesterone significantly reduced the risk of preterm birth occurring at <28 to <34 gestational weeks (relative risks, 0.41-0.68), composite neonatal morbidity and mortality (relative risk, 0.59; 95% confidence interval, 0.33-0.98), and birthweight <1500 g (relative risk, 0.55; 95% confidence interval, 0.33-0.94) in twin gestations with a transvaginal sonographic cervical length ≤25 mm (6 studies; 95 women and 190 fetuses/infants). The quality of evidence was moderate for all these outcomes. CONCLUSION: Vaginal progesterone does not prevent preterm birth, nor does it improve perinatal outcomes in unselected twin gestations, but it appears to reduce the risk of preterm birth occurring at early gestational ages and of neonatal morbidity and mortality in twin gestations with a sonographic short cervix. However, more evidence is needed before recommending this intervention to this subset of patients.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Conde-Agudelo A, Romero R, Rehal A, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in twin gestations: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023. PMID: 37196896. doi:10.1016/j.ajog.2023.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。